As more CBD products have gone mainstream and are now available in major retailers like CVS, Walgreens, and Kroger, American Premium Water Corporation (HIPH) shares looks undervalued

As more and more states legalize marjiuana, federal legalization in the U.S. seems inevitable. Not only are more states passing legislation to permit recreational use, but a vast majority of Americans also support legalization.

According to a recent survey, Pew Research found that 91% of people in the U.S. believe marijuana should be legal for either medical or recreational use, with 60% in favor of both.

President Joe Biden is in favor of decriminalizing marijuana, while Senate Majority Leader Chuck Schumer is ready to push ahead with full legalization efforts even if Biden isn’t completely on board just yet.

The trend for growth continues as the CBD market could surpass $23.6 billion by 2025

CBD products have gone mainstream and are now available in major retailers like CVS, Walgreens, and Kroger. Over the past few years many companies have announced they are getting into the CBD business

According to High Yield Insights, “roughly 40 percent of U.S. adults age 21 and over indicated a willingness to explore CBD under the right conditions.” High Yield Insights is not the only research firm talking about big numbers; New Frontier Data conducted a nationally represented survey of consumers that said 86% of Americans know of CBD, while 18% of Americans have tried CBD at least once. Another survey with surprising results is one that was completed by the Arthritis Foundation, where 26 percent of patients with arthritis said they use CBD to treat their symptoms.

American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of Nano technologies paired without cannabidiol (CBD) to treat health disorders and enhance quality of life.

The company recently announced that it has come to terms on the acquisition of licenses to distribute and retail hemp cannabinoids in the State of New York as part of the State’s program to establish quality control standards on the industry. The Company expects to close the transaction by the end of the 1st half 2021. (Disclosure: The Company acquired these licenses from a New York entity that was owned by CEO, Ryan Fishoff. The proposed consideration for the licenses is nominal.) 

According to a report released by Grandview Research, New York State’s cannabis market is expected to be worth over $7 billion by 2025. The New York State hemp cannabinoid program oversees the licensing of processors, distributors, and retailers, setting quality control standards that all hemp products must meet including manufacturing, packaging and labeling and laboratory testing requirements. 

Goldman Small Cap Research, a sponsored research provider focused on microcap stocks, has issued a new research update. This update highlights the impact of the Company recent developments, including its joint venture with Cali Bear (www.calibear.life).  

In the sponsored research update, analyst Rob Goldman affirms his price target of $0.0425 and his investment thesis, noting that the news reflects a milestone event that is wide-reaching for the Company in terms of revenue, cross-selling opportunities, and a reach into new markets. 

For investors HIPH has an attractive share structure that can allow its shares to move up easily on positive developments.

The company’s portfolio includes the LALPINA Hydro and LALPINA CBD brands (www.lalpinahydrocbd.com), Cali Bear (www.calibear.life) Vanexxe (www.vanexxe.com) plant + body essentials (www.plantbodyessentials.co).

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here

FEATURED

Advertisment